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Acquired Generalized Lipodystrophy Associated with 




Lipodystrophies are rare diseases characterized by loss
of fat tissue in the body. This group of diseases may be 
congenital or acquired, and each has several subtypes 
which may be generalized or local. The congenital generalized
form is also known as Berardinelli-Seip syndrome (1). 
Hyperinsulinemia, insulin resistance, hyperglycemia, 
hypertriglyceridemia, and fatty liver are other features of this
syndrome. The pathogenesis of congenital generalized 
lipodystrophy is not clear. Fat tissue has endocrine, paracrine,
and autocrine effects in addition to its role in energy storage (2).
The components of the classical complement pathway are
also synthesized in fat tissue (3). Consequently, it has been
proposed that complement activation may be the 
cause of lipodystrophy (4-7). Recently, three cases with 
autoimmune hepatitis and acquired lipodystrophy with low
complement 4 (C4) levels have been reported (8). This paper 
presents a case with autoimmune hepatitis who developed
generalized lipodystrophy.
Case Report
A six-year-old girl was admitted to the hospital with 
abdominal distention, respiratory distress, and hyperglycemia.
She had been followed by the departments of gastroenterology
and cardiology with diagnoses of autoimmune hepatitis and
hypertrophic cardiomyopathy.
A liver biopsy was performed at age one and a half years
because of hypertransaminasemia (aspartate transaminase
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reported as chronic hepatitis. At that time, total bilirubin 
level was 1.1 mg/dL and direct bilirubin level was 0.7
mg/dL. Serum triglyceride level was elevated (496 mg/dL).
Six months later (at the age of two years), the patient was
readmitted with fever and haematuria. Her liver was 6 cm
and spleen 2 cm palpable below the costal margin. The 
laboratory evaluation at that time revealed elevated 
transaminases (AST 152 and ALT 166 U/L), positive 
antimitochondrial antibodies (AMA) and anti-liver-kidney
microsome antibodies (LKM1). Nephrocalcinosis was 
reported on ultrasonographic examination. 
The patient was born to a sixteen-year-old mother by 
vaginal delivery at full term and her weight was 2250 g. The
parents reported that her appearance was normal during
the first year of her life. Subsequently, they had noted that
she appeared thinner with reduced subcutaneous tissue.
There was no family history of consanguinity and her 
three-year-old sister was healthy.
On physical examination, the patient’s weight (23 kg)
and height (117 cm) were above the 97th percentile. Her
weight for height was normal. She was mentally dull. 
She had coarse facial features with generalized loss of 
subcutaneous fat and prominent muscularity (Figure 1). Her
tonsils were hypertrophic. Remarkable acanthosis nigricans
was present over the neck, axilla, and umbilicus (Figure 2).
The abdomen was protuberant and distended with 
hepatosplenomegaly. The liver was palpable 6 cm below
the costal margin and the spleen was massively enlarged,
extending to the inguinal area. Dyspnea with subcostal 
retractions was present and coarse crackles were audible
over the entire chest. There was a systolic murmur of 2-3/6
magnitude over the mesocardiac area. Her pubertal status
was Tanner stage III for thelarche (pseudothelarche) and
stage I for pubarche (Figure 3).
The patient had lipomastia that simulated breast 
enlargement corresponding to a Tanner stage III thelarche,
although the tissue was lipoid rather than glandular. This
was confirmed by prepubertal gonadotropin and estradiol 
levels. The bone age was also appropriate for chronological age.
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Figure 1. General appearance of the patient, note the coarse face, ge-
neralized loss of subcutaneous fat, prominent muscularity, and 
protuberant abdomen
Figure 3. Note the acanthosis nigricans on the axilla and 
pseudothelarche
Figure 2. Remarkable acanthosis nigricans over the neckThe laboratory results were as follows: Hb 12.8 g/dL,
MCV 86 fl, platelet count 131.000/mm
3, WBC 10 140/mm
3,
glucose 185 mg/dL, ALT 88 U/L, AST 110 U/L, total bilirubin
1.9 mg/dL, direct bilirubin 0.5 mg/dL, triglyceride 438
mg/dL, total cholesterol 158 mg/dL, LDL 20 mg/dL, and
HDL 20 mg/dL. Anti-smooth muscle antibody (ASMA) and
anti-nuclear antibody (ANA) both were positive at 1/100 
dilution. Two hours after a glucose load of 1.75 g/kg blood
glucose level was 258 mg/dL, HbA1c 6.8% and insulin level
was 642.9 mIU/mL, revealing a state of insulin resistance
and type 2 diabetes mellitus (DM). 
Serum adiponectin (<0.3 mcg/mL) and leptin 
(0.1 mcg/L) levels were both below the detectable range.
Serum complement 3 (C3) level was normal (1.11 g/L 
[0.8-2.14]), but serum C4 level was low (0.1 g/L [0.13-0.6]).
Immune globulin G (IgG) was elevated at 24.2 g/L 
(4.9-16.1). Anti-LKM was positive. 
Acquired generalized lipodystrophy was diagnosed 
based on these findings. Metformin therapy was started at
a dose of 850 mg bid orally along with dietary intervention.
Although the patient did not attend the follow-up visits 
regularly, during her last visit it was noted that acanthosis
nigricans decreased tremendously. One year after starting
metformin and diet therapy, her fasting blood glucose and
insulin levels were 123 mg/dL and 85.2 mIU/mL, respectively.
HbA1c was 6.2%. Recently, corticosteroid therapy was
started for autoimmune hepatitis. Currently, the patient is
still being followed for cardiomyopathy, autoimmune 
hepatitis, type 2 diabetes, and insulin resistance. 
The parents provided verbal and written permission for
taking and publishing photographs of the patient. 
Discussion
The risk of type 2 DM with increasing fat and insulin 
resistance is well-known (9). On the other hand, loss of fat
tissue may also be associated with insulin resistance and
type 2 DM. It has been suggested that insulin resistance in
lipodystrophy may be associated with accumulation of 
ectopic fat tissue in the liver, in skeletal muscles, and in
pancreatic beta cells (10). The diminished fat tissue may 
lead to increased fatty acids, which may be stored as 
triglycerides in the liver and muscles. In the long term, the
increased free fatty acids lead to a reduced beta-cell 
response to hyperglycemia. In congruence with the loss of
fat tissue, leptin and adiponectin levels decrease to 
undetectable levels (8). As we have observed in our patient,
serum adiponectin and leptin levels that reveal the amount
of fat in the body are decreased in this condition. It has 
also been reported that resistin level is reduced and tumor
necrosis factor (TNF)-α which is a proinflammatory cytokine
is increased (11). Recently, leptin therapy has been 
reported to correct hyperglycemia, dyslipidemia, and 
hepatic steatosis both in congenital and acquired forms of
lipodystrophy (12-15). Unfortunately, leptin therapy was not
available for our patient. 
The pathogenesis of acquired generalized lipodystrophy
is not completely understood at present. Many patients
with congenital lipodystrophy have low C3 levels associated
with mesangiocapillary glomerulonephritis (7). This possibility
could have explained the haematuria and proteinuria in our
patient. Serum C3 concentration is decreased by activation
of the alternate pathway. Acquired lipodystrophy frequently
coexists with other autoimmune diseases. Severe hemolytic
anemia, autoimmune thyroid disease, and polyneuropathy
may be present. Although rare, neurological problems have
been reported (16). Although nonalcoholic fatty liver is seen
in all patients with generalized lipodystrophy, in some 
patients, fatty liver has been reported to occur before 
lipodystrophy is evident (17). The hypertrophic cardiomyopathy
in our patient was an expected finding associated with
hyperinsulinemia. 
Ziegler (18) reported acquired lipodystrophy for the first
time in 1928. The first patient with acquired lipodystrophy
who presented with steatohepatitis was reported in 1989 (19).
Serum C4 of the present case was decreased. Savage
et al (8) have reported the association of diminished C4 and
autoimmune hepatitis in three patients with generalized 
lipodystrophy and proposed that low C4 might be the 
causative factor in this disease. On the other hand, low C4
is also a well-known finding in patients with autoimmune
hepatitis  (20,21). It has been reported that children with 
autoimmune hepatitis have an isolated partial deficiency of
the complement component C4, which is genetically 
determined and is associated with the possession of the si-
lent gene C4AQO at the C4A locus (22-24). Therefore, low
C4, which is a feature of autoimmune diseases, could be
genetically determined and could have resulted in both 
autoimmune hepatitis and lipodystrophy, if it is the causative
factor. Unfortunately, detailed genetic analysis was not 
available for this case. It appears that further genetic 
studies can be performed to enlighten the possible 
autoimmune basis of acquired lipodystrophies. 
In conclusion, our patient provides another example for
acquired generalized lipodystrophy in which autoimmune
hepatitis was the initial manifestation. Since autoimmune
hepatitis may precede lipodystrophy, this entity must be
kept in mind as a diagnostic possibility. We do not know yet
whether low C4, which may be inherent, is a triggering 
factor for both autoimmune hepatitis and acquired 
lipodystrophy, or not.
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